Search
Eupraxia Pharmaceuticals Inc
EPRXAdd to Watchlist
6.690USD
-0.020-0.30%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
413.50MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.30%
5 Days
+1.36%
1 Month
+3.72%
6 Months
-11.62%
Year to Date
-11.39%
1 Year
+24.12%
Key Figures
6.750Open
6.820High
359.47KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.58%Turnover Ratio
6.710Prev. Close
6.560Low
1.66MTurnover
LossP/E Static
3.83P/B
0.00%Div Yield TTM
-50.97%ROA
12.86052wk High
1.41Volume Ratio
-25.50MNet Profit
61.81MShares
-0.9991EPS TTM
1.49Beta
-84.74%ROE
5.20052wk Low
3.87%Amplitude
--Gross Margin
413.50MMarket Cap
1.18Reward/Risk
3.43%Risk Rate
TradingKey Stock Score
No stock score available due to insufficient data.
Eupraxia Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Eupraxia Pharmaceuticals Inc Info
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Ticker SymbolEPRX
CompanyEupraxia Pharmaceuticals Inc
CEOHelliwell (James A)
Websitehttps://eupraxiapharma.com/home/default.aspx
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Eupraxia Pharmaceuticals Inc (EPRX)?
The current price of Eupraxia Pharmaceuticals Inc (EPRX) is 6.69.
What is the symbol of Eupraxia Pharmaceuticals Inc?
The ticker symbol of Eupraxia Pharmaceuticals Inc is EPRX.
What is the 52-week high of Eupraxia Pharmaceuticals Inc?
The 52-week high of Eupraxia Pharmaceuticals Inc is 12.86.
What is the 52-week low of Eupraxia Pharmaceuticals Inc?
The 52-week low of Eupraxia Pharmaceuticals Inc is 5.20.
What is the market capitalization of Eupraxia Pharmaceuticals Inc?
The market capitalization of Eupraxia Pharmaceuticals Inc is 413.50M.
Is Eupraxia Pharmaceuticals Inc (EPRX) currently rated as Buy, Hold, or Sell?
According to analysts, Eupraxia Pharmaceuticals Inc (EPRX) has an overall rating of Buy, with a price target of 16.44.
What is the Earnings Per Share (EPS TTM) of Eupraxia Pharmaceuticals Inc (EPRX)?
The Earnings Per Share (EPS TTM) of Eupraxia Pharmaceuticals Inc (EPRX) is -0.97.